Lung
- AJT Admin
- Jun 15
- 1 min read
In preparation for the 2026 Banff Meeting to be held Oct 5-9, 2026 in Banff, Canada - we are soliciting input from the international transplant community on guiding the discussions at the in-person meeting. Please share your thoughts on the following questions to each of the sessions in your area of interest listed in the blog: (the full program and registration information for the 2026 Banff meeting can be found here: https://site.pheedloop.com/event/2026banffmeeting/schedule)*
*Some final changes to session and presentation titles might occur.
What are the most important knowledge gaps and/or unmet clinical needs for this session?
What questions would you ask the moderators and speakers at this session?
Banff Lung Concurrent: the past, present and future of multicenter study for lung allograft |
Biobanking for multicenter studies: does and don’t |
Recommendation from expert biostatisticians: what test should we use for multicenter lung transplant study? |
Digital pathology integration for multicenter studies |
Regulatory barriers for multicentral and international study: how do we overcome them |
Lessons learned from Prior multicenter study: best practices moving forward |
How to work with multidisciplinary teams for multicenter studies |
What are the most important knowledge gaps and/or unmet clinical needs for this session?
What questions would you ask the moderators and speakers at this session?
Banff Lung Concurrent II: |
Working group discussion for multicenter study |
Group discussion for project #1: hypothesis, methodology, anticipated barriers |
Finalize actional plan and timeline for project #1 |
Group discussion for project #2: hypothesis, methodology, anticipated barriers |
Finalize actional plan and timeline for project #2 |
A major unmet need is the integration of molecular diagnostics, particularly transcriptomic and other omics-based approaches, into lung allograft pathology. Current histopathologic classifications incompletely capture the biological heterogeneity underlying acute injury and chronic dysfunction. Future multi-center efforts should focus on developing and validating molecular signatures that complement conventional pathology, improve diagnostic precision, and enable earlier identification of patients at risk for progression from acute lung allograft dysfunction, who could be included in mechanism-targeted clinical trials.